{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:11:15Z","timestamp":1768871475342,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A new concept for treatment of infections is induction of our own antimicrobial peptides and the presented novel class of inducer, aroylated phenylenediamines (APDs), gives up to 20 to 30-fold induction of the human antimicrobial peptide LL-37, <jats:italic>in vitro<\/jats:italic>. In addition, oral administration of an APD in a rabbit model of Shigellosis resulted in recovery from the infection in a few days implying that APD\u2019s are promising candidates for treatment of infections.<\/jats:p>","DOI":"10.1038\/srep36692","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T10:07:33Z","timestamp":1478686053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Potent Inducers of Endogenous Antimicrobial Peptides for Host Directed Therapy of Infections"],"prefix":"10.1038","volume":"6","author":[{"given":"H.","family":"Ottosson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nyl\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Miraglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. H.","family":"Gudmundsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Raqib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Agerberth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,9]]},"reference":[{"key":"BFsrep36692_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095\u20132128 (2012).","journal-title":"Lancet"},{"key":"BFsrep36692_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1086\/524891","volume":"46","author":"B Spellberg","year":"2008","unstructured":"Spellberg, B. et al. The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155\u2013164 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep36692_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher, H. W. et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1\u201312 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep36692_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","volume":"6","author":"AK Marr","year":"2006","unstructured":"Marr, A. K., Gooderham, W. J. & Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6, 468\u2013472 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFsrep36692_CR5","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1111\/j.1742-4658.2011.08302.x","volume":"278","author":"A Cederlund","year":"2011","unstructured":"Cederlund, A., Gudmundsson, G. H. & Agerberth, B. Antimicrobial peptides important in innate immunity. FEBS J. 278, 3942\u20133951 (2011).","journal-title":"FEBS J."},{"key":"BFsrep36692_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389\u2013395 (2002).","journal-title":"Nature"},{"key":"BFsrep36692_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nri1180","volume":"3","author":"T Ganz","year":"2003","unstructured":"Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710\u2013720 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"BFsrep36692_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00109-002-0350-6","volume":"80","author":"M Zaiou","year":"2002","unstructured":"Zaiou, M. & Gallo, R. L. Cathelicidins, essential gene-encoded mammalian antibiotics. J. Mol. Med. (Berl). 80, 549\u2013561 (2002).","journal-title":"J. Mol. Med. (Berl)."},{"key":"BFsrep36692_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"REW Hancock","year":"2006","unstructured":"Hancock, R. E. W. & Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551\u20131557 (2006).","journal-title":"Nat. Biotechnol."},{"key":"BFsrep36692_CR10","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","volume":"76","author":"J Overhage","year":"2008","unstructured":"Overhage, J. et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76, 4176\u20134182 (2008).","journal-title":"Infect. Immun."},{"key":"BFsrep36692_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","volume":"2","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. EBioMedicine 2, 690\u2013698 (2015).","journal-title":"EBioMedicine"},{"key":"BFsrep36692_CR12","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1080\/15548627.2015.1075110","volume":"11","author":"RS Rekha","year":"2015","unstructured":"Rekha, R. S. et al. Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy 11, 1688\u20131699 (2015).","journal-title":"Autophagy"},{"key":"BFsrep36692_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/84627","volume":"7","author":"D Islam","year":"2001","unstructured":"Islam, D. et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat. Med. 7, 180\u2013185 (2001).","journal-title":"Nat. Med."},{"key":"BFsrep36692_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/gut.52.5.735","volume":"52","author":"J Schauber","year":"2003","unstructured":"Schauber, J. et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut 52, 735\u2013741 (2003).","journal-title":"Gut"},{"key":"BFsrep36692_CR15","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1128\/AAC.00818-09","volume":"53","author":"J Steinmann","year":"2009","unstructured":"Steinmann, J., Halld\u00f3rsson, S., Agerberth, B. & Gudmundsson, G. H. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob. Agents Chemother. 53, 5127\u20135133 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep36692_CR16","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.4049\/jimmunol.173.5.2909","volume":"173","author":"T-T Wang","year":"2004","unstructured":"Wang, T.-T. et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173, 2909\u20132912 (2004).","journal-title":"J. Immunol."},{"key":"BFsrep36692_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1096\/fj.04-3284com","volume":"19","author":"AF Gombart","year":"2005","unstructured":"Gombart, A. F., Borregaard, N. & Koeffler, H. P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 19, 1067\u20131077 (2005).","journal-title":"FASEB J."},{"key":"BFsrep36692_CR18","doi-asserted-by":"publisher","first-page":"9178","DOI":"10.1073\/pnas.0602888103","volume":"103","author":"R Raqib","year":"2006","unstructured":"Raqib, R. et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc. Natl. Acad. Sci. USA 103, 9178\u20139183 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep36692_CR19","doi-asserted-by":"publisher","first-page":"e20637","DOI":"10.1371\/journal.pone.0020637","volume":"6","author":"P Sarker","year":"2011","unstructured":"Sarker, P. et al. Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One 6, e20637 (2011).","journal-title":"PLoS One"},{"key":"BFsrep36692_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.micinf.2013.08.007","volume":"15","author":"A Al-Mamun","year":"2013","unstructured":"Al-Mamun, A. et al. Treatment with phenylbutyrate in a pre-clinical trial reduces diarrhea due to enteropathogenic Escherichia coli: link to cathelicidin induction. Microbes Infect. 15, 939\u2013950 (2013).","journal-title":"Microbes Infect."},{"key":"BFsrep36692_CR21","doi-asserted-by":"publisher","first-page":"e0138340","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily, A. et al. Significant Effects of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS One 10, e0138340 (2015).","journal-title":"PLoS One"},{"key":"BFsrep36692_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1753425913493338","volume":"20","author":"F Nyl\u00e9n","year":"2014","unstructured":"Nyl\u00e9n, F. et al. Boosting innate immunity: development and validation of a cell-based screening assay to identify LL-37 inducers. Innate Immun. 20, 364\u2013376 (2014).","journal-title":"Innate Immun."},{"key":"BFsrep36692_CR23","doi-asserted-by":"publisher","first-page":"33274","DOI":"10.1038\/srep33274","volume":"6","author":"E Miraglia","year":"2016","unstructured":"Miraglia, E., et al. Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1\u03b1 transcription factors. Sci Rep. 6, 33274 (2016).","journal-title":"Sci Rep."},{"key":"BFsrep36692_CR24","doi-asserted-by":"publisher","first-page":"e92919","DOI":"10.1371\/journal.pone.0092919","volume":"9","author":"JJ Cody","year":"2014","unstructured":"Cody, J. J., Markert, J. M. & Hurst, D. R. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One 9, e92919 (2014).","journal-title":"PLoS One"},{"key":"BFsrep36692_CR25","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","volume":"20","author":"JC Bressi","year":"2010","unstructured":"Bressi, J. C. et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 20, 3142\u20133145 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFsrep36692_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ni.1825","volume":"11","author":"NH Salzman","year":"2010","unstructured":"Salzman, N. H. et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol. 11, 76\u201383 (2010).","journal-title":"Nat Immunol."},{"key":"BFsrep36692_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1462-5822.2005.00530.x","volume":"7","author":"P Bergman","year":"2005","unstructured":"Bergman, P. et al. Neisseria gonorrhoeae downregulates expression of the human antimicrobial peptide LL-37. Cell Microbiol. 7, 1009\u20131017 (2005).","journal-title":"Cell Microbiol."},{"key":"BFsrep36692_CR28","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/j.1462-5822.2008.01227.x","volume":"10","author":"K Chakraborty","year":"2008","unstructured":"Chakraborty, K. et al. Bacterial exotoxins downregulate cathelicidin (hCAP-18\/LL-37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol. 10, 2520\u20132537 (2008).","journal-title":"Cell Microbiol."},{"key":"BFsrep36692_CR29","doi-asserted-by":"publisher","first-page":"e68875","DOI":"10.1371\/journal.pone.0068875","volume":"8","author":"H Lofton","year":"2013","unstructured":"Lofton, H., Pr\u00e4nting, M., Thulin, E. & Andersson, D. I. Mechanisms and Fitness Costs of Resistance to Antimicrobial Peptides LL-37, CNY100HL and Wheat Germ Histones. Plos One, 8, e68875 (2013).","journal-title":"Plos One"},{"key":"BFsrep36692_CR30","doi-asserted-by":"publisher","first-page":"20162","DOI":"10.1074\/jbc.M113.459560","volume":"288","author":"L Ryan","year":"2013","unstructured":"Ryan, L. et al. Anti-antimicrobial Peptides. Folding-mediated host defense antagonists. J. Biol. Chem. 288, 20162\u201320172 (2013).","journal-title":"J. Biol. Chem."},{"key":"BFsrep36692_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/ph7050545","volume":"7","author":"G Wang","year":"2014","unstructured":"Wang, G. Human Antimicrobial Peptides and Proteins. Pharmaceuticals, 7, 545\u2013594 (2014).","journal-title":"Pharmaceuticals"},{"key":"BFsrep36692_CR32","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.bmc.2007.12.007","volume":"16","author":"L Gediya","year":"2008","unstructured":"Gediya, L., Belosay, A., Khandelwal, A., Purushottamachar, P. & Njar, V. C. O. Improved Synthesis of Histone Deacetylase Inhibitors (HDIs) (MS-275 and CI-994) and Inhibitory Effects of HDIs Alone or in Combination with RAMBAs or Retinoids on Growth of Human LNCaP Prostate Cancer Cells and Tumor Xenografts. Bioorg Med Chem 16, 3352\u20133360 (2008).","journal-title":"Bioorg Med Chem"},{"key":"BFsrep36692_CR33","first-page":"193","volume":"44","author":"M Pinto","year":"1982","unstructured":"Pinto, M. et al. Enterocytic differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium. Biol. Cell 44, 193\u2013196 (1982).","journal-title":"Biol. Cell"},{"key":"BFsrep36692_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/ard.58.8.493","volume":"58","author":"G Cunnane","year":"1999","unstructured":"Cunnane, G. et al. Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. Ann. Rheum. Dis. 58, 493\u2013499 (1999).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep36692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36692","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep36692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:32:01Z","timestamp":1672878721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep36692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep36692"],"URL":"https:\/\/doi.org\/10.1038\/srep36692","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,9]]},"assertion":[{"value":"5 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Three of the authors (RS, GHG, BA) are co-founders of Akthelia that applied for a patent for use of APD\u2019s in treatment of infections.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36692"}}